Trials / Terminated
TerminatedNCT03936959
A Study of LY3434172, a PD-1 and PD-L1 Bispecific Antibody, in Advanced Cancer
A Phase 1 Study of LY3434172, a Bispecific Antibody Monotherapy in Advanced Solid Tumors
- Status
- Terminated
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 10 (actual)
- Sponsor
- Eli Lilly and Company · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The main purpose of this study is to evaluate the safety and tolerability of the study drug LY3434172, a PD-1/PD-L1 bispecific antibody, in participants with advanced solid tumors.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | LY3434172 | Administered IV |
Timeline
- Start date
- 2019-05-24
- Primary completion
- 2020-03-30
- Completion
- 2021-04-29
- First posted
- 2019-05-03
- Last updated
- 2025-01-15
- Results posted
- 2025-01-15
Locations
5 sites across 5 countries: United States, Australia, Belgium, France, South Korea
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT03936959. Inclusion in this directory is not an endorsement.